Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization -44% Improvement Relative Risk Case 10% c19hcq.org Kamstrup et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 60,334 patients in Denmark Higher hospitalization with HCQ (not stat. sig., p=0.25) Kamstrup et al., Int. J. Infectious Diseases, doi:10.1016/j.ijid.2021.05.076 Favors HCQ Favors control
Hydroxychloroquine as a primary prophylactic agent against sars-cov-2 infection: a cohort study
Kamstrup et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.05.076
Kamstrup et al., Hydroxychloroquine as a primary prophylactic agent against sars-cov-2 infection: a cohort study, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.05.076
Jun 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective HCQ users in Denmark, not showing a significant difference, however authors do not adjust for the very different baseline risk for systemic autoimmune disease patients.
Authors appear unaware of research in the area, for example saying that "currently, no obvious connection exists between a known rheumatological disorder and the risk of contracting SARS-CoV-2". Many papers show that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, e.g., Ferri et al. show OR 4.42, p<0.001 [Ferri].
Supplementary data is not currently available. This study is excluded in the after exclusion results of meta analysis: not fully adjusting for the different baseline risk of systemic autoimmune patients.
risk of hospitalization, 44.0% higher, OR 1.44, p = 0.25, treatment 5,488, control 54,846, RR approximated with OR.
risk of case, 10.0% lower, HR 0.90, p = 0.23, treatment 188 of 5,488 (3.4%), control 2,040 of 54,846 (3.7%), NNT 340, adjusted Cox proportional hazards regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kamstrup et al., 1 Jun 2021, retrospective, population-based cohort, Denmark, peer-reviewed, 21 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: International Journal of Infectious Diseases 108 (2021) 370–376 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: www.elsevier.com/locate/ijid Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study Peter Kamstrupa,* , Pradeesh Sivapalana , Josefin Eklöfa , Nils Hoyera , Charlotte Suppli Ulrikb , Lars Pedersenc, Therese S. Lapperrec , Zitta Barrella Harboed,i , Uffe Bodtgere, Rasmus Dahlin Bojesenf , Kjell E.J. Håkanssonb , Casper Tidemandsenb , Karin Armbrustera , Andrea Browatzkid , Howraman Meterana , Christian Niels Meyerg, Kristoffer Grundtvig Skaaruph , Mats Christian Højbjerg Lassenh , Jens D. Lundgreni,j , Tor Biering-Sørensenh,i,k , Jens-Ulrik Jensena,i,j a Section of Respiratory Medicine, Department of Medicine, Copenhagen University Hospital Herlev and Gentofte Hospital, Hellerup, Denmark Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark Department of Respiratory Medicine, Copenhagen University Hospital-Bispebjerg, Copenhagen, Denmark d Department of Pulmonary and Infectious Diseases, Copenhagen University Hospital North Zealand, Hillerød, Denmark e Respiratory Research Unit, Department of Respiratory Medicine, Næstved, Slagelse and Ringsted Hospitals, Næstved, Denmark f Department of Surgery, Næstved, Slagelse and Ringsted Hospitals, Slagelse, Denmark g Department of Medicine, Zealand University Hospital, Roskilde, Denmark h Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte Hospital, Hellerup, Denmark i Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark j PERSIMUNE & CHIP: Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark k Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark b c A R T I C L E I N F O A B S T R A C T Article history: Received 16 April 2021 Received in revised form 17 May 2021 Accepted 28 May 2021 Objective: Hydroxychloroquine has been proposed as a primary prophylactic agent against coronavirus disease 2019 (COVID-19). This study aimed to investigate if patients treated with hydroxychloroquine for a non-COVID-19 indication had a lower risk of verified infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) compared with matched controls. Methods: A cohort comprising all persons in Denmark collecting hydroxychloroquine prescriptions in 2020 and 2019 (i.e., both during and before SARS-CoV-2 was confirmed in Denmark), matched by age and sex with controls, was studied. Data were collected using the Danish national registries, which contain complete information on patient health data, prescriptions and microbiological test results. The main outcome was microbiologically verified SARS-CoV-2 infection. Results: In total, 5488 hydroxychloroquine users were matched with 54,486 non-users. At baseline, the groups differed in terms of diagnoses of pulmonary disease, cardiovascular disease, renal disease, gastrointestinal/metabolic disease and dementia, as well as treatment with antirheumatic drugs. The final model was adjusted for these potential confounders. Use of hydroxychloroquine for non-COVID-19 indications was not associated with any change in confirmed SARS-CoV-2 (hazard ratio 0.90, 95% confidence interval 0.76–1.07). This result was robust in..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit